SCYNEXIS, Inc. (SCYX)
NASDAQ$0.932
Market Cap
$36.33M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
356 of 924
Rank in Industry
18 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SCYX Insider Trading Activity
SCYX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $27,400 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Angulo Gonzalez David | Chief Executive Officer | 1 | $27,400 | 0 | $0 | $27,400 |
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the …
Insider Activity of SCYNEXIS, Inc.
Over the last 12 months, insiders at SCYNEXIS, Inc. have bought $27,400 and sold $0 worth of SCYNEXIS, Inc. stock.
On average, over the past 5 years, insiders at SCYNEXIS, Inc. have bought $237,633 and sold $4.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Angulo Gonzalez David (Chief Executive Officer) — $27,400.
The last purchase of 20,000 shares for transaction amount of $27,400 was made by Angulo Gonzalez David (Chief Executive Officer) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, SCYNEXIS, Inc.
| 2024-09-12 | Angulo Gonzalez David | Chief Executive Officer | 20,000 0.054% | $1.37 | $27,400 | -10.45% | ||
| 2022-04-26 | Taglietti Marco | Chief Executive Officer | 75,000 0.226% | $3.00 | $225,000 | -8.26% | ||
| 2022-04-26 | Sukenick Scott | General Counsel | 3,500 0.0105% | $3.00 | $10,500 | -8.26% | ||
| 2021-01-22 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 319,000 1.2567% | $8.24 | $2.63M | -12.08% | |
| 2021-01-21 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 95,000 0.3717% | $7.38 | $701,100 | -2.46% | |
| 2021-01-20 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 185,000 0.717% | $7.43 | $1.37M | -3.77% | |
| 2020-12-21 | Taglietti Marco | Chief Executive Officer | 40,000 0.3797% | $6.25 | $250,000 | +17.98% | ||
| 2020-12-21 | Angulo Gonzalez David | Chief Medical Officer | 1,600 0.0152% | $6.25 | $10,000 | +17.98% | ||
| 2020-12-21 | Macdonald Guy | director | 8,000 0.0759% | $6.25 | $50,000 | +17.98% | ||
| 2020-12-21 | Francois Eric | Chief Financial Officer | 600 0.0057% | $6.25 | $3,750 | +17.98% | ||
| 2020-12-21 | Sukenick Scott | General Counsel | 1,600 0.0152% | $6.25 | $10,000 | +17.98% | ||
| 2020-12-21 | Tinmouth Brian Philippe | director | 8,000 0.0759% | $6.25 | $50,000 | +17.98% | ||
| 2020-12-21 | ANIDO ARMANDO | director | 5,000 0.0475% | $6.25 | $31,250 | +17.98% | ||
| 2020-12-21 | GILMAN STEVEN C | director | 4,000 0.038% | $6.25 | $25,000 | +17.98% | ||
| 2020-12-21 | HANHAM ANN | director | 3,200 0.0304% | $6.25 | $20,000 | +17.98% | ||
| 2019-12-12 | Taglietti Marco | Chief Executive Officer | 333,334 0.461% | $1.00 | $333,334 | -0.94% | ||
| 2019-08-21 | Taglietti Marco | Chief Executive Officer | 19,000 0.0171% | $0.56 | $10,545 | -19.28% | ||
| 2019-08-20 | Taglietti Marco | Chief Executive Officer | 1,000 0.0009% | $0.56 | $555 | -19.19% | ||
| 2019-08-15 | Taglietti Marco | Chief Executive Officer | 20,030 0.0349% | $1.01 | $20,230 | -12.98% | ||
| 2019-04-17 | Taglietti Marco | Chief Executive Officer | 50,000 0.095% | $1.63 | $81,500 | -32.30% |
Total: 67
*Gray background shows transactions not older than one year
Insider Historical Profitability
9.37%
| Angulo Gonzalez David | Chief Executive Officer | 507871 1.3029% | $473,335.77 | 12 | 0 | +18.38% |
| ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 1240575 3.1825% | $1.16M | 1 | 0 | |
| Ventech Capital II | 10 percent owner | 414211 1.0626% | $386,044.65 | 1 | 0 | |
| Nothias Jean-Yves | director | 295077 0.757% | $275,011.76 | 1 | 0 | |
| FCPR Biotechnology Fund | 10 percent owner | 295077 0.757% | $275,011.76 | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,051,022 | 1591 | -12.84% | $76.27M | |
$22,899,264 | 81 | 34.90% | $26.7M | |
$125,860,243 | 57 | -4.48% | $54.94M | |
SCYNEXIS, Inc. (SCYX) | $2,740,482 | 50 | 9.37% | $36.33M |
$30,209,812 | 45 | -1.91% | $8.36M |
SCYX Institutional Investors: Active Positions
| Increased Positions | 28 | +68.29% | 539,467 | +4.1% |
| Decreased Positions | 13 | -31.71% | 2M | -12.24% |
| New Positions | 12 | New | 309,363 | New |
| Sold Out Positions | 5 | Sold Out | 561,822 | Sold Out |
| Total Postitions | 56 | +36.59% | 12M | -8.14% |
SCYX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Federated Hermes, Inc. | $2,982.00 | 7.62% | 2.9M | -700,000 | -19.47% | 2024-12-31 |
| Kingdon Capital Management, L.L.C. | $2,304.00 | 5.89% | 2.24M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $1,711.00 | 4.37% | 1.66M | -25,405 | -1.51% | 2024-12-31 |
| Avidity Partners Management Lp | $1,266.00 | 3.23% | 1.23M | -219,818 | -15.17% | 2024-12-31 |
| Amh Equity Ltd | $645.00 | 1.65% | 626,052 | +26,052 | +4.34% | 2024-12-31 |
| Acadian Asset Management Llc | $481.00 | 1.23% | 467,268 | -73,415 | -13.58% | 2024-12-31 |
| Blackrock, Inc. | $439.00 | 1.12% | 426,214 | +571 | +0.13% | 2024-12-31 |
| Bridgeway Capital Management, Llc | $436.00 | 1.11% | 423,486 | +640 | +0.15% | 2024-12-31 |
| Geode Capital Management, Llc | $417.00 | 1.07% | 405,064 | +6,208 | +1.56% | 2024-12-31 |
| Oconnor, A Distinct Business Unit Of Ubs Asset Management Am | $201.00 | 0.51% | 195,393 | +35,233 | +22% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.